| Record ID | marc_loc_2016/BooksAll.2016.part40.utf8:166185738:1700 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part40.utf8:166185738:1700?format=raw |
LEADER: 01700cam a22004337i 4500
001 2012554827
003 DLC
005 20150814081115.0
008 130701t20122012nyua b 001 0 eng d
010 $a 2012554827
020 $a9781622570911
020 $a162257091X
035 $a(OCoLC)ocn793582192
040 $aBTCTA$beng$cBTCTA$erda$dYDXCP$dBWX$dYOU$dCOA$dOCLCO$dOCLCF$dOCLCQ$dOCLCO$dOCLCA$dDLC
042 $alccopycat
043 $an-us---
050 00 $aRA401.5$b.F42 2012
082 00 $a615.1072/4$223
245 00 $aFDA drug approval :$belements and considerations /$cTimothy I. King and Thomas R. Baker, editors.
264 1 $aNew York :$bNova Biomedical :$bNova Science Publishers,$c[2012]
264 4 $c©2012
300 $ax, 142 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aPharmacology - research, safety testing and regulation
490 1 $aGovernment procedures and operations
504 $aIncludes bibliographical references and index.
610 10 $aUnited States.$bFood and Drug Administration.
650 0 $aDrug approval$zUnited States.
650 0 $aClinical trials$zUnited States.
610 17 $aUnited States.$bFood and Drug Administration.$2fast$0(OCoLC)fst00549734
650 7 $aClinical trials.$2fast$0(OCoLC)fst00864429
650 7 $aDrug approval.$2fast$0(OCoLC)fst00898661
651 7 $aUnited States.$2fast$0(OCoLC)fst01204155
710 1 $aKing, Timothy I.,$eeditor.
710 1 $aBaker, Thomas R.,$eeditor.
830 0 $aPharmacology - research, safety testing and regulaton series.
830 0 $aGovernment procedures and operations.